Obrixtamig – Medxy AI

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis
Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety
Maintenance Romidepsin Therapy Post-AHCT in Peripheral T-Cell Lymphoma: Feasibility and Outcomes from a Multicenter Phase 2 Study
Kissing Bugs and Chagas Disease: Understanding the Hidden Threat in the United States
Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging AI artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity MASH MASLD mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch thử nghiệm lâm sàng tirzepatide type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Scroll to Top